Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11207511 | 0.98 | HPGD (0.44) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11964113 | 0.94 | ALDH1A1 (0.41) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14975085 | 0.80 | NPC1 (0.54) | NPC1MAPT | |
| SCHEMBL19398923 | 0.71 | PI4KA (0.44) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11963738 | 0.70 | GRM5 (0.42) | ALDH1A1SMN1; SMN2KMT2ALMNAMAPK1 | |
| SCHEMBL875204 | 0.69 | POLB (0.43) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14975241 | 0.69 | MEN1 (0.35) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4099800 | 0.69 | MEN1 (0.38) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19398929 | 0.69 | PDPK1 (0.46) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL932341 | 0.68 | KDM4E (0.46) | HPGDALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250101104-A1 | BISPECIFIC MOLECULE WITH TUNABLE AFFINITY TO A TARGETED ANTIGEN | MABSWITCH INC (US) | 2025-03-27 | — | — | US | disclosed |
| CN-112996795-B | Fused tricyclic derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-113227103-B | Trisubstituted heteroaryl derivatives as SRC homo-2 phosphatase inhibitors | 尼坎治疗公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-02-20 | — | — | US | disclosed |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11459340-B2 | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2012027359-A1 | METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN | ALKERMES, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110009571-A1 | SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS | ALCON RESEARCH, LLC | 2011-01-13 | — | — | US | disclosed |
| US-20100210792-A1 | DRUG DELIVERY | LANDEC CORPORATION | 2010-08-19 | — | — | US | disclosed |
| US-20090263346-A1 | Systems and methods for delivery of drugs | LANDEC CORPORATION | 2009-10-22 | — | — | US | disclosed |
| US-20080269105-A1 | Delivery of drugs | ALCON RESEARCH, LLC | 2008-10-30 | — | — | US | disclosed |
| US-20070287703-A1 | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1773830-A1 | FUSED PYRIMIDONES USEFUL IN THE TREATMENT AND THE PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008523-A1 | FUSED PYRIMIDONES USEFUEL IN THE TREATMENT AND THE PREVENTION OF CANCER | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | WO | disclosed |
| US-4113868-A | 5,6-DIHYDROPYRIMIDIN-4(3H)ONE DERIVATIVES, AND ANTIEDEMA COMPOSITIONS AND METHODS EMPLOYING THEM | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1978-09-12 | — | — | US | disclosed |
| US-3929787-A | 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones | SQUIBB & SONS INC | 1975-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263346-A1 | Systems and methods for delivery of drugs | CYCS, CTRC, PPIC | HPGD 2176/4885ALDH1A1 1982/4885SMN1; SMN2 3647/4885 |
| US-20070287703-A1 | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer | DHFR, DPYD, TYMP | HPGD 728/4885ALDH1A1 1047/4885SMN1; SMN2 2067/4885 |
| US-20230167134-A1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS | SRC, PTPRCAP, PTPRC | HPGD 3593/4885ALDH1A1 4595/4885SMN1; SMN2 3732/4885 |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN2, PTPN5 | HPGD 4310/4885ALDH1A1 3978/4885SMN1; SMN2 1644/4885 |
| US-20080269105-A1 | Delivery of drugs | ABCB11, ABCB1, LPXN | HPGD 2006/4885ALDH1A1 3172/4885SMN1; SMN2 2086/4885 |
| US-20100210792-A1 | DRUG DELIVERY | ABCB11, VEGFA, ABCB1 | HPGD 2142/4885ALDH1A1 3160/4885SMN1; SMN2 1075/4885 |
| US-11459340-B2 | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors | SRC, PTPRCAP, PTPN2 | HPGD 3715/4885ALDH1A1 4313/4885SMN1; SMN2 3637/4885 |
| US-12264167-B2 | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | HPGD 3593/4885ALDH1A1 4595/4885SMN1; SMN2 3732/4885 |
| US-11518772-B2 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | SRC, PTPRCAP, PTPRC | HPGD 3593/4885ALDH1A1 4595/4885SMN1; SMN2 3732/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | HPGD 4310/4885ALDH1A1 3978/4885SMN1; SMN2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.